Current pharmacotherapies of alcoholism: A U.S. perspective

American Journal on Addictions

Volumn 12, Issue SUPPL. 1, 2003, Pages s53-s68

  Anton, Raymond F ^a   Swift, Robert M ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; CALCIUM CARBIMIDE; CITALOPRAM; DISULFIRAM; FLUOXETINE; GLUTAMATE RECEPTOR ANTAGONIST; NALMEFENE; NALTREXONE; ONDANSETRON; OPIATE ANTAGONIST; PAROXETINE; SEROTONIN 3 ANTAGONIST; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ABSTINENCE; ALCOHOL WITHDRAWAL; ALCOHOLISM; CLINICAL TRIAL; DRINKING BEHAVIOR; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LIVER TOXICITY; METHODOLOGY; NAUSEA; NEUROBIOLOGY; NONHUMAN; PSYCHOSOCIAL CARE; REVIEW; VOMITING;

EID: 0038249078     PISSN: 10550496     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2003.tb00496.x     Document Type: Review

References (90)

1. Project MATCH Research Group. Project MATCH: rationale and methods for a multisite clinical trial matching patients to alcoholism treatment. Alcohol Clin Exp Res. 1993;17:1130-1145.
2. Koob GF, Roberts AJ, Schulteis G, et al. Neurocircuitry targets in ethanol reward and dependence. Alcohol Clin Exp Res. 1998;22(1):3-9.
3. George MS, Anton RF, Bloomer C, et al. Activation of prefrontal cortex and anterior thalamus in alcoholic subjects on exposure to alcohol-specific cues. Arch Gen Psychiatry. 2001;58(4):345-352.
4. Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA. 1999;281(14):1318-1325.
5. Swift RM. Drug therapy for alcohol dependence. New Engl J Med. 1999;340(19):1482-1490.
6. Kranzler HR. Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research. Alcohol Alcohol. 2000;35(6):537-547.
7. Anton RF. Pharmacologic approaches to the management of alcoholism. J Clin Psychiatry. 2001;62(suppl 20):11-17.
8. Drobes DJ, Anton RF, Thomas SE, Voronin K. A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene. Neuropsychopharmacology, in press.
9. Anton RF, Drobes DJ. Clinical measurement of craving in addiction. Psychiatr Annals. 1998;28(10):553-560.
10. Anton R. What is craving? Models and implications for treatment. Alcohol Health Res World. 1999;23(3):165-179.
11. Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism. JAMA. 1986;256(11):1449-1455.
12. Allen JP, Litten RZ, Anton R. Measures of alcohol consumption in perspective. In: Litten RZ & Allen JP, eds. Measuring Alcohol Consumption: Psychosocial and Biologic Methods. Totowa, NJ: Humana Press; 1992:205-226.
13. O'Farrell TJ, Allen JP, Litten RZ. Disulfiram (antabuse) contracts with psychotherapy and disulfiram. NIDA Res Monogr. 1995;150:65-91.
14. Carroll KM, Nich C, Ball SA, McCane E, Rounsaville BJ. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction. 1998;93(5):713-727.
15. Sinclair JD. Laboratory animal research in the discovery and development of the new alcoholism treatment using opioid antagonists. Scand J Lab Anim Sci. 1996;23:379-390.
16. Kornet M, Goosen C, Van Ree JM. Effect of naltrexone on alcohol consumption during chronic alcohol drinking and after a period of imposed abstinence in free-choice drinking rhesus monkeys. Psychopharmacology. 1991;104:367-376.
17. Williams KL, Woods JH. Conditioned effects produced by naltrexone doses that reduce ethanol-reinforced responding in rhesus monkeys. Alcohol Clin Exp Res. 1999;23(4):708-715.
18. Benjamin D, Grant ER, Pohorecky LA. Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res. 1993;621:137-140.
19. Gonzales RA, Weiss F. Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J Neurosci. 1998;18(24):10663-10671.
20. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876-880.
21. O'Malley SS, Jaffe AJ, Chang G, et al. Naltrexone and coping skills therapy for alcohol dependence. Arch Gen Psychiatry. 1992;49:881-887.
22. Anton RF, Moak DH, Waid LR, et al. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics. Am J Psychiatry. 1999;156(11):1758-1764.
23. Morris PLP, Hopwood M, Whelan G, Gardiner J, Drummond E. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction. 2001;96:1565-1573.
24. Heinala P, Alho H, Kiianmaa K, et al. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2001;21:287-292.
25. Latt NC, Jurd S, Houseman J, Wutzke SE. Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med J Aust. 2002;176:530-534.
26. Volpicelli JR, Rhines KC, Rhines JS, et al. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry. 1997;54:737-742.
27. Chick J, Anton R, Checinski K, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 2000;35:587-593.
28. Monti PM, Rohsenow DJ, Swift RM, et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res. 2001;25(11):1634-1647.
29. Kranzler HR, Modesto-Lowe V, Van Kirk J. Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology. 2000;22(5):493-503.
30. Krystal JH, Cramer JS, Krol WF, et al. Naltrexone in the treatment of alcohol dependence. New Engl J Med. 2001;345(24):1734-1739.
31. Mason BJ, Ritvo EC, Morgan RO, et al. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HC1 for alcohol dependence. Alcohol Clin Exp Res. 1994;18(5):1162-1167.
32. Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry. 1999;56(8):719-724.
33. Anton RF, Moak DH, Latham PK, et al. Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of outpatient alcoholics. J Clin Psychopharmacol. 2001;21(1):72-77.
34. Pettinati HM, Volpicelli JR, Pierce JD Jr, O'Brien CP. Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol-dependent patients. J Addict Dis. 2000;19(1):71-83.
35. Rohsenow DJ, Colby SM, Monti PM, et al. Predictors of compliance with naltrexone among alcoholics. Alcohol Clin Exp Res. 2000;24(10):1542-1549.
36. Oncken C, Van Kirk J, Kranzler HR. Adverse effects of oral naltrexone: analysis of data from two clinical trials. Psychopharmacology. 2001;154(4):397-402.
37. Kranzler HR, Modesto-Lowe V, Nuwayser ES. Sustained-release naltrexone for alcoholism treatment: a preliminary study. Alcohol Clin Exp Res. 1998;22(5):1074-1079.
38. Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res. 2001;25(9):1335-1341.
39. Streeton C, Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol. 2001;36(6):544-552.
40. Hersh D, Van Kirk JR, Kranzler HR. Naltrexone treatment of comorbid alcohol and cocaine use disorders. Psychopharmacology. 1998;139:44-52.
41. McCaul B, Wand GS, Sullivan J, Mumford G, Quigley J. Beta-naltrexol level predicts alcohol relapse. Alcohol Clin Exp Res. 1997;21(3):32A.
42. Bohn MJ, Kranzler HR, Beazoglou D, Staehler BA. Naltrexone and brief counseling to reduce heavy drinking: results of a small clinical trial. Am J Addict. 1994;3(2):91-99.
43. Kranzler HR, Tennen H, Penta C, Bohn MJ. Targeted naltrexone treatment of early problem drinkers. Addict Behav. 1997;22(3):431-436.
44. Oslin D, Liberto JG, O'Brien J, Krois S. Tolerability of naltrexone in treating older alcohol-dependent patients. Am J Addict. 1997;6(3):266-270.
45. Croop RS, Faulkner EB, Labriola DF. The Naltrexone Study Usage Group. The safety profile of naltrexone in the treatment of alcoholism: results from a multicenter usage study. Arch Gen Psychiatry. 1997;54:1130-1135.
46. Kim SW, Grant JE, Adson DE, Remmel RP. A preliminary report on possible naltrexone and nonsteroidal analgesic interactions. J Clin Psychopharmacol. 2001;21(6):632-634.
47. Littleton J, Zieglgänsberger W. Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am J Addict. 2003;12(Suppl 1):S3-S11.
48. Littleton J. Acamprosate in alcohol dependence: how does it work? Addiction. 1995;90:1179-1188.
49. Berton F, Francesconi WG, Madamba SG, Zieglgansberger W, Siggins GR. Acamprosate enhances N-methyl-D-apartate receptor-mediated neurotransmission but inhibits presynaptic GABA(B) receptors in nucleus accumbens neurons. Alcohol Clin Exp Res. 1998;22(1):183-191.
50. Naassila M, Hammoumi S, Legrand E, Durbin P, Daoust M. Mechanism of action of acamprosate, part I: characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol Clin Exp Res. 1998;22(4):802-809.
51. Al Qatari M, Bouchenafa O, Littleton J. Mechanism of action of acamprosate, part II: ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol Clin Exp Res. 1998;22(4):810-814.
52. Kalluri HSG, Mehta AK, Ticku MK. Up-regulation of NMDA receptor subunits in rat brain following chronic ethanol treatment. Mol Brain Res. 1998;58:221-224.
53. Pierce RC, Reeder DC, Hicks J, Morgan ZR, Kalivas PW. Ibotenic acid lesions of the dorsal prefrontal cortex disrupt the expression of behavioral sensitization to cocaine. Neuroscience. 1998;82(4):1103-1114.
54. Spanagel R, Holter SM, Allingham K, Landgraf R, Zieglgansberge W. Acamprosate and alcohol, I: effects on alcohol intake following alcohol deprivation in the rat. Eur J Pharmacol. 1996;305:39-44.
55. LeMagnen J, Tran G, Durlach J. Lack of effects of Ca-acetyl homotaurine on chronic and acute toxicities of alcohol in the rat. Alcohol. 1987;4:103-108.
56. Nalpas B, Dabadie H, Parot P, Paccalin J. Acamprosate: from pharmacology to therapeutics. Encephale. 1990;16(3):175-179.
57. Mason B, Ownby R. Acamprosate for the treatment of alcohol dependence: a review of double-blind, placebo-controlled trials. CNS Spectrums. 2000;5(2):58-69.
58. Kranzler HR, Anton RF. Implications of recent neuropsychopharmacologic research for understanding the etiology and development of alcoholism. J Consult Clin Psychol. 1994;62:1116-1126.
59. Linnoila M, Eckardt M, Durcan M. Interactions of serotonin with ethanol: clinical and animal studies. Psychopharmacol Bull. 1987;23:452-457.
60. LeMarquand D, Phil RO, Benkelfat C. Serotonin and alcohol intake, abuse, and dependence: findings of animal studies. Biol Psychol. 1994;36(6):395-421.
61. Kranzler HR, Burleson JA, Del Boca FK, et al. Buspirone treatment of anxious-alcoholics: a placebo-controlled trial. Arch Gen Psychiatry. 1994;51:720-731.
62. Naranjo CA, Sellers EM, Roach CA, et al. Zimelidine-induced variations in alcohol intake by nondepressed heavy drinkers. Clin Pharmacol Ther. 1984;35:374-381.
63. Naranjo CA, Poulos CX, Bremner KE, Lanctot KL. Fluoxetine attenuates alcohol intake and desire to drink. Int Clin Psychopharmacol. 1994;9(3):163-172.
64. Pettinati HM, Oslin D, Decker K. Role of serotonin and serotonin-selective pharmacotherapy in alcohol dependence. CNS Spectrums. 2000;5(2):33-46.
65. Pettinati HM, Volpicelli JR, Kranzler HR, et al. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res. 2000;24(7):1041-1049.
66. Virkkunen M, Linnoila M. Serotonin in early-onset alcoholism. Recent Dev Alcohol. 1997;13:173-189.
67. Rodd-Henricks ZA, McKinzie DL, Edmundson VE, et al. Serotonin-3 receptor antagonists reduce alcohol intake during acquisition and maintenance but not following a period of alcohol deprivation in alcohol preferring (P) rats. Alcohol Clin Exp Res. 1999;20(5):49A.
68. Hodge CW, Samson HH, Lewis RS, Erickson HL. Specific decreases in ethanol- but no water-reinforced responding produced by the 5-HT3 antagonist ICS205-930. Alcohol. 1993;10:191-196.
69. Grant KA. The role of 5-HT3 receptors in drug dependence. Drug Alcohol Depend. 1995;38:155-171.
70. Johnson BA, Cowen PJ. Alcohol-induced reinforcement: dopamine and 5-HT3 receptor interactions in animals and humans. Drug Development Research. 1993;30:153-169.
71. Sellers EM, Toneatto T, Romach MK, et al. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res. 1994;18(4):879-885.
72. Johnson BA, Roache JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients. JAMA. 2000;284(8):963-971.
73. Dorus W, Ostrow DG, Anton R, et al. Lithium treatment of depressed and nondepressed alcoholics. JAMA. 1989;262(12):1646-1652.
74. Lejoyeux M, Ades J. Evaluation of lithium treatment in alcoholism. Alcohol Alcohol. 1993;28(3):273-279.
75. Malcolm R, Myrick H, Brady KT, Ballenger JC. Update on anticonvulsants for the treatment of alcohol withdrawal. Am J Addict. 2001;10(suppl):16-23.
76. Malcolm R, Ballenger JC, Sturgis ET, Anton R. Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal. Am J Psychiatry. 1989;146:617-621.
77. Stuppaeck CH, Pycha R, Miller C, Whitworth AB, Oberbauer H, Fleischhacker WW. Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double-blind study. Alcohol and Alcoholism. 1992;27:153-158.
78. Malcolm R, Roberts JS, Wang W, Myrick H, Anton RF. Multiple previous detoxifications are associated with less responsive treatment and heavier drinking during an index outpatient detoxification. Alcohol. 2000;22:159-164.
79. Mueller TI, Stout RT, Rudden S, et al. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res. 1997;21(1):86-92.
80. Brady KT, Myrick H, Henderson S. Coffey SF. Divalproex in the prevention of relapse to alcohol use. Drug Alcohol Depend., in press.
81. Besson J, Aeby F, Kasas A, Lehert P, Potgieter A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res. 1998;22(3):573-579.
82. Johnson BA, Ait-Daoud N, Prihoda TJ. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence. Alcohol Clin Exp Res. 2000;24(5):737-742.
83. Ait-Daoud N, Johnson BA, Prihoda TJ, Hargita ID. Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence. Psychopharmacology. 2001;154:23-27.
84. COMBINE Study Research Group. Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods. Alcohol Clin Exp Res. In press.
85. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, Baehr M, Naber D, Wiedemann K. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism. Arch Gen Psychiatry 2003;60:92-99.
86. Mason BJ, Goodman AM, Dixon RM, et al. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology. 2002;27(4):596-606.
87. Johnson BA, O'Malley SS, Ciraulo DA, et al. Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate both alone and combined in alcohol dependent subjects. J Clin Psychopharmacol. In press.
88. COMBINE Study Research Group. Testing combined pharmacotherapies and behavioral interventions in alcohol dependence (the COMBINE Study): a pilot feasibility study. Alcohol: Clin Exp Res. In press.
89. Alcoholics Anonymous. The AA Member - Medications and Other Drugs: A Report from a Group of Physicians in New York. New York: AA World Services; 1984.
90. Rychtarik R, Conners G, Dermen K, Stasiewicz P. Alcoholics anonymous and the use of medications to prevent relapse: an anonymous survey of member attitudes. J Stud Alcohol. 1998;61:134-138.